Alpha 2.0

» Articles » PMID: 39076283

Antiatherosclerotic Effect and Molecular Mechanism of Salidroside

Overview

Overview

Journal Rev Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Jul 30

PMID 39076283

Authors

Authors

Si-Fan Fei

De-Bing Tong

Fang Jia

Affiliations

Affiliations

Soon will be listed here.

Abstract

Atherosclerotic cardiovascular disease is currently the leading cause of death worldwide. Its pathophysiological basis includes endothelial dysfunction, macrophage activation, vascular smooth muscle cell (VSMC) proliferation, lipid metabolism, platelet aggregation, and changes in the gut microbiota. Salidroside has beneficial effects on atherosclerosis through multiple pathways. In this review, we present studies on the regulatory effect of salidroside on atherosclerosis. Furthermore, we report the protective effects of salidroside against atherosclerosis by ameliorating endothelial dysfunction, suppressing macrophage activation and polarization, inhibiting VSMC proliferation, adjusting lipid metabolism, attenuating platelet aggregation, and modulating the gut microbiota. This review provides further understanding of the molecular mechanism of salidroside and new ideas for atherosclerosis management.

Citing Articles

Salidroside and exercise performance in healthy active young adults - an exploratory, randomized, double-blind, placebo-controlled study.

Schwarz N, Stratton M, Colquhoun R, Manganti A, Sherbourne M, Mourey F J Int Soc Sports Nutr. 2024; 21(1):2433744.

PMID: 39601362 PMC: 11610317. DOI: 10.1080/15502783.2024.2433744.

Effects of salidroside on atherosclerosis: potential contribution of gut microbiota.

Fei S, Hou C, Jia F Front Pharmacol. 2024; 15:1400981.

PMID: 39092226 PMC: 11292615. DOI: 10.3389/fphar.2024.1400981.

References

1.

Wang H, Wu T, Qi J, Wang Y, Luo X, Ning Q . Salidroside attenuates LPS-stimulated activation of THP-1 cell-derived macrophages through down-regulation of MAPK/NF-kB signaling pathways. J Huazhong Univ Sci Technolog Med Sci. 2013; 33(4):463-469. DOI: 10.1007/s11596-013-1143-6. View

2.

Zhang X, Xie L, Long J, Xie Q, Zheng Y, Liu K . Salidroside: A review of its recent advances in synthetic pathways and pharmacological properties. Chem Biol Interact. 2021; 339:109268. DOI: 10.1016/j.cbi.2020.109268. View

3.

Pirillo A, Norata G, Catapano A . LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. 2013; 2013:152786. PMC: 3723318. DOI: 10.1155/2013/152786. View

4.

Li H, Xi Y, Xin X, Tian H, Hu Y . Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis. Biomed Pharmacother. 2020; 124:109915. DOI: 10.1016/j.biopha.2020.109915. View

5.

Zhaolin Z, Guohua L, Shiyuan W, Zuo W . Role of pyroptosis in cardiovascular disease. Cell Prolif. 2018; 52(2):e12563. PMC: 6496801. DOI: 10.1111/cpr.12563. View

6.

Vanhoutte P, Shimokawa H, Feletou M, Tang E . Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf). 2015; 219(1):22-96. DOI: 10.1111/apha.12646. View

7.

Al Bander Z, Nitert M, Mousa A, Naderpoor N . The Gut Microbiota and Inflammation: An Overview. Int J Environ Res Public Health. 2020; 17(20). PMC: 7589951. DOI: 10.3390/ijerph17207618. View

8.

Ni J, Li Y, Li W, Guo R . Salidroside protects against foam cell formation and apoptosis, possibly via the MAPK and AKT signaling pathways. Lipids Health Dis. 2017; 16(1):198. PMC: 5635575. DOI: 10.1186/s12944-017-0582-7. View

9.

Lewis C, Taylor W . Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease. Am J Physiol Heart Circ Physiol. 2020; 319(6):H1227-H1233. PMC: 7792706. DOI: 10.1152/ajpheart.00612.2020. View

10.

Xie Z, Lu H, Yang S, Zeng Y, Li W, Wang L . Salidroside Attenuates Cognitive Dysfunction in Senescence-Accelerated Mouse Prone 8 (SAMP8) Mice and Modulates Inflammation of the Gut-Brain Axis. Front Pharmacol. 2020; 11:568423. PMC: 7759146. DOI: 10.3389/fphar.2020.568423. View

11.

Zhu Z, Li J, Zhang X . Salidroside protects against ox-LDL-induced endothelial injury by enhancing autophagy mediated by SIRT1-FoxO1 pathway. BMC Complement Altern Med. 2019; 19(1):111. PMC: 6543685. DOI: 10.1186/s12906-019-2526-4. View

12.

Xu M, Wang X, Li Y, Geng X, Jia X, Zhang L . Arachidonic Acid Metabolism Controls Macrophage Alternative Activation Through Regulating Oxidative Phosphorylation in PPARγ Dependent Manner. Front Immunol. 2021; 12:618501. PMC: 8211451. DOI: 10.3389/fimmu.2021.618501. View

13.

Zhuang X, Maimaitijiang A, Li Y, Shi H, Jiang X . Salidroside inhibits high-glucose induced proliferation of vascular smooth muscle cells via inhibiting mitochondrial fission and oxidative stress. Exp Ther Med. 2017; 14(1):515-524. PMC: 5488502. DOI: 10.3892/etm.2017.4541. View

14.

Xiong J, Kawagishi H, Yan Y, Liu J, Wells Q, Edmunds L . A Metabolic Basis for Endothelial-to-Mesenchymal Transition. Mol Cell. 2018; 69(4):689-698.e7. PMC: 5816688. DOI: 10.1016/j.molcel.2018.01.010. View

15.

Paone S, Baxter A, Hulett M, Poon I . Endothelial cell apoptosis and the role of endothelial cell-derived extracellular vesicles in the progression of atherosclerosis. Cell Mol Life Sci. 2018; 76(6):1093-1106. PMC: 11105274. DOI: 10.1007/s00018-018-2983-9. View

16.

Makarenko V, Usatyuk P, Yuan G, Lee M, Nanduri J, Natarajan V . Intermittent hypoxia-induced endothelial barrier dysfunction requires ROS-dependent MAP kinase activation. Am J Physiol Cell Physiol. 2014; 306(8):C745-52. PMC: 3989715. DOI: 10.1152/ajpcell.00313.2013. View

17.

Majithia A, Bhatt D . Novel Antiplatelet Therapies for Atherothrombotic Diseases. Arterioscler Thromb Vasc Biol. 2019; 39(4):546-557. PMC: 6445601. DOI: 10.1161/ATVBAHA.118.310955. View

18.

Zheng X, Wu Z, Wei Y, Dai J, Yu G, Yuan F . Induction of autophagy by salidroside through the AMPK-mTOR pathway protects vascular endothelial cells from oxidative stress-induced apoptosis. Mol Cell Biochem. 2016; 425(1-2):125-138. DOI: 10.1007/s11010-016-2868-x. View

19.

Zhang Y, Li C, Huang Y, Zhao S, Xu Y, Chen Y . EOFAZ inhibits endothelial‑to‑mesenchymal transition through downregulation of KLF4. Int J Mol Med. 2020; 46(1):300-310. PMC: 7255478. DOI: 10.3892/ijmm.2020.4572. View

20.

Nording H, Baron L, Langer H . Platelets as therapeutic targets to prevent atherosclerosis. Atherosclerosis. 2020; 307:97-108. DOI: 10.1016/j.atherosclerosis.2020.05.018. View